Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo

Antiviral Research

Volumn 54, Issue 2, 2002, Pages 79-88

  Carr, J ^a   Ives, J ^a   Kelly, L ^b   Lambkin, R ^b   Oxford, J ^b   Mendel, D ^c   Tai, L ^c   Roberts, N ^a  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c GILEAD SCIENCES   (United States)

Author keywords

Influenza; Neuraminidase; Oseltamivir phosphate; Resistance; Tamiflu

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ARGININE; DRUG METABOLITE; LYSINE; OSELTAMIVIR; PRODRUG; SIALIDASE; SIALIDASE INHIBITOR; VIRUS ENZYME;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DOG; DRUG IDENTIFICATION; FEMALE; FERRET; FEVER; HUMAN; IN VITRO STUDY; INFLAMMATION; INFLUENZA; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTIVITY; VIRUS ISOLATION; VIRUS MUTATION; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ACETAMIDES; ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FERRETS; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; LUNG; MICE; MICE, INBRED BALB C; MUTATION; NEURAMINIDASE; OSELTAMIVIR; SEQUENCE ANALYSIS, DNA; SPECIFIC PATHOGEN-FREE ORGANISMS; VIRUS REPLICATION;

ANIMALIA; INFLUENZA VIRUS; INFLUENZAVIRUS A; MUSTELA; MUSTELA PUTORIUS FURO;

EID: 0036224388     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(01)00215-7     Document Type: Article

References (24)

1. Generation and characterisation of a mutant of influenza A virus selected with the neuraminidase inhibitor RWJ-270201
2. Virological assessment in vitro and in vivo of an influenza H1N1 virus with a H274Y mutation in the neuraminidase gene
3. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets
4. Influenza virus neuraminidase: Structure, antibodies, and inhibitors
5. Phenotypic and genotypic assay of influenza virus neuraminidase indicates a low incidence of viral drug resistance during treatment with oseltamivir
6. Zanamivir and rimantadine susceptibility of virus isolates from a clinical trial comparing the use of zanamivir or rimantadine in the control of nursing home influenza outbreaks
7. Catalytic and framework mutations in the neuraminidase active site of influenza that are resistant to 4-Guanidino-Neu5Ac2en
8. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus
9. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir
10. Amantadine & rimantadine - Clinical aspects
11. Centers for Disease Control and Prevention. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
12. An oseltamivir treatment-selected influenza A/N2 virus with a R292K mutation in the neuraminidase gene has reduced infectivity in vivo
13. An oseltamivir treatment-selected influenza A/Wuhan/359/95 virus with a E119V mutation in the neuraminidase gene has reduced infectivity in vivo
14. Management of influenza: Use of new antivirals and resistance in perspective
15. An epidemiological model of influenza to investigate the potential transmission of drug resistant virus during community use antiviral treatment for influenza
16. Resistance of influenza viruses to neuraminidase inhibitors - A review
17. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors
18. Fluorometric assay of neuraminidase with a sodium (4-Methylumbelliferyl-a-D-N-Acetylneuraminate) substrate
19. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071
20. Monitoring of viral susceptibility: New challenges with the development of influenza NA inhibitors
21. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized, controlled trial
22. Characterisation of an influenza A virus variant selected in vitro in the presence of the neuraminidase inhibitor, GS4071
23. Oral oseltamivir treatment of influenza in children
24. Position statement: Global neuraminidase inhibitor susceptibility network